scholarly journals Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma

2016 ◽  
Vol 14 (7) ◽  
pp. 820-824 ◽  
Author(s):  
Andre P. Fay ◽  
Guillermo de Velasco ◽  
Thai H. Ho ◽  
Eliezer M. Van Allen ◽  
Bradley Murray ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Exome Sequencing ◽  
Whole Exome Sequencing ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Whole Exome ◽  
Extreme Phenotypes

scholarly journals The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma

2021 ◽  
pp. 1194-1200
Author(s):  
Amanda Pilling ◽  
Christopher Wee ◽  
Eliezer Bar-Meir ◽  
Gregory Dyson ◽  
Ok Hwang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Precision Medicine ◽  
Exome Sequencing ◽  
Whole Exome Sequencing ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Molecular Basis ◽  
Drug Sensitivity ◽  
Whole Exome

Through elucidating the genetic mechanisms of drug sensitivity, precision medicine aims to improve patient selection and response to therapy. Exceptional responders are patients that exhibit exquisite and durable responses to targeted therapy, providing a rare opportunity to identify the molecular basis of drug sensitivity. We identified an exceptional responder to everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR) pathway, in a patient with advanced renal cell carcinoma. Through whole-exome sequencing on pretreatment and metastatic tumor DNA, we identified alterations in several mTOR pathway genes, with several mutations implicated in mTOR activation. Importantly, these alterations are currently not included in commercially available next-generation sequencing panels, suggesting that precision medicine is still limited in its ability to predict responses to mTOR-targeted therapies. Further research to discover and validate predictive biomarkers of response to everolimus and other targeted therapies is urgently needed. Given the rarity of patients with exceptional responses to targeted agents, cooperative efforts to understand the molecular basis for these phenotypes are essential.

scholarly journals Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

2019 ◽  
Vol 17 (1) ◽  
pp. e227-e234 ◽  
Author(s):  
Tiphaine Cholley ◽  
Antoine Thiery-Vuillemin ◽  
Samuel Limat ◽  
Marion Hugues ◽  
Fabien Calcagno ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Economic Burden ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

2013 ◽  
Vol 49 (15) ◽  
pp. 3169-3175 ◽  
Author(s):  
M.R. Matrana ◽  
C. Duran ◽  
A. Shetty ◽  
L. Xiao ◽  
B.J. Atkinson ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals PD46-05 INTRA-TUMOR MOLECULAR HETEROGENEITY OF CLEAR CELL RENAL CELL CARCINOMA SEEMS TO CONTRIBUTE TO THE DIVERSITY OF RESPONSE TO TARGETED THERAPIES

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Baoan Hong ◽  
Yong Yang ◽  
Sheng Guo ◽  
Qixiang Li ◽  
Ning Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Clear Cell ◽  
Molecular Heterogeneity ◽  
Cell Renal Cell Carcinoma

scholarly journals Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine

2013 ◽  
Vol 137 (4) ◽  
pp. 467-480 ◽  
Author(s):  
Rajen Goyal ◽  
Elizabeth Gersbach ◽  
Ximing J. Yang ◽  
Stephen M. Rohan
Keyword(s):  
Renal Cell Carcinoma ◽  
Differential Diagnosis ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Clear Cell ◽  
Renal Tumor ◽  
Renal Tumors ◽  
Cell Renal Cell Carcinoma ◽  
Immunohistochemical Stains

Context.—The World Health Organization classification of renal tumors synthesizes morphologic, immunohistochemical, and molecular findings to define more than 40 tumor types. Of these, clear cell (conventional) renal cell carcinoma is the most common malignant tumor in adults and—with the exception of some rare tumors—the most deadly. The diagnosis of clear cell renal cell carcinoma on morphologic grounds alone is generally straightforward, but challenging cases are not infrequent. A misdiagnosis of clear cell renal cell carcinoma has clinical consequences, particularly in the current era of targeted therapies. Objective.—To highlight morphologic mimics of clear cell renal cell carcinoma and provide strategies to help differentiate clear cell renal cell carcinoma from other renal tumors and lesions. The role of the pathologist in guiding treatment for renal malignancies will be emphasized to stress the importance of proper tumor classification in patient management. Data Sources.—Published literature and personal experience. Conclusions.—In challenging cases, submission of additional tissue is often an inexpensive and effective way to facilitate a correct diagnosis. If immunohistochemical stains are to be used, it is best to use a panel of markers, as no one marker is specific for a given renal tumor subtype. Selection of limited markers, based on a specific differential diagnosis, can be as useful as a large panel in reaching a definitive diagnosis. For renal tumors, both the presence and absence of immunoreactivity and the pattern of labeling (membranous, cytoplasmic, diffuse, focal) are important when interpreting the results of immunohistochemical stains.

Array-comparative genomic hybridization to predict resistance to VEGF-targeted therapies in patients with metastatic clear cell renal cell carcinoma.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16074-e16074
Author(s):  
Solene-Florence Kammerer-Jacquet ◽  
Frederic Dugay ◽  
Laurence Cluzeau ◽  
Angelique Brunot ◽  
Julien Dagher ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Comparative Genomic Hybridization ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Array Comparative Genomic Hybridization ◽  
Clear Cell ◽  
Comparative Genomic ◽  
Genomic Hybridization ◽  
Cell Renal Cell Carcinoma

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

2017 ◽  
Vol 83 ◽  
pp. 237-246 ◽  
Author(s):  
Chiara Ciccarese ◽  
Roberto Iacovelli ◽  
Matteo Brunelli ◽  
Francesco Massari ◽  
Davide Bimbatti ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Clinical Trials ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Clear Cell ◽  
Meta Analysis ◽  
Randomised Clinical Trials ◽  
Cell Renal Cell Carcinoma

scholarly journals Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models

Oncotarget ◽  
2017 ◽  
Vol 8 (30) ◽  
pp. 49839-49850 ◽  
Author(s):  
Baoan Hong ◽  
Yong Yang ◽  
Sheng Guo ◽  
Shayiremu Duoerkun ◽  
Xiaohu Deng ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Targeted Therapies ◽  
Renal Cell ◽  
Clear Cell ◽  
Molecular Heterogeneity ◽  
Cell Renal Cell Carcinoma ◽  
Patient Derived Xenograft ◽  
Xenograft Models
Sign in / Sign up

Export Citation Format

Share Document